Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29


Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.

Ahmed MSU, Salam AB, Yates C, Willian K, Jaynes J, Turner T, Abdalla MO.

Int J Nanomedicine. 2017 Sep 19;12:6973-6984. doi: 10.2147/IJN.S139011. eCollection 2017.


UPAR targeted molecular imaging of cancers with small molecule-based probes.

Ding F, Chen S, Zhang W, Tu Y, Sun Y.

Bioorg Med Chem. 2017 Oct 15;25(20):5179-5184. doi: 10.1016/j.bmc.2017.08.034. Epub 2017 Aug 22. Review.


Urokinase Plasminogen Activator Receptor-PET with <sup>68</sup>Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand.

Skovgaard D, Persson M, Kjaer A.

PET Clin. 2017 Jul;12(3):311-319. doi: 10.1016/j.cpet.2017.02.003. Epub 2017 Apr 8. Review.


Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).

Loft MD, Sun Y, Liu C, Christensen C, Huang D, Kjaer A, Cheng Z.

Amino Acids. 2017 Jun;49(6):1089-1100. doi: 10.1007/s00726-017-2407-4. Epub 2017 Mar 18.


Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.

Skovgaard D, Persson M, Kjaer A.

PET Clin. 2017 Apr;12(2):243-255. doi: 10.1016/j.cpet.2016.12.005. Epub 2017 Jan 31. Review.


uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.

Christensen A, Juhl K, Persson M, Charabi BW, Mortensen J, Kiss K, Lelkaitis G, Rubek N, von Buchwald C, Kjær A.

Oncotarget. 2017 Feb 28;8(9):15407-15419. doi: 10.18632/oncotarget.14282.


PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.

Skovgaard D, Persson M, Kjaer A.

Clin Transl Imaging. 2016;4(6):457-465. doi: 10.1007/s40336-016-0197-4. Epub 2016 Jul 4. Review.


Safety, Dosimetry, and Tumor Detection Ability of <sup>68</sup>Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging.

Skovgaard D, Persson M, Brandt-Larsen M, Christensen C, Madsen J, Klausen TL, Holm S, Andersen FL, Loft A, Berthelsen AK, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A.

J Nucl Med. 2017 Mar;58(3):379-386. doi: 10.2967/jnumed.116.178970. Epub 2016 Sep 8.


Novel Strategy for Preparing Dual-Modality Optical/PET Imaging Probes via Photo-Click Chemistry.

Sun L, Ding J, Xing W, Gai Y, Sheng J, Zeng D.

Bioconjug Chem. 2016 May 18;27(5):1200-4. doi: 10.1021/acs.bioconjchem.6b00115. Epub 2016 Apr 27.


Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.

Juhl K, Christensen A, Persson M, Ploug M, Kjaer A.

PLoS One. 2016 Feb 1;11(2):e0147428. doi: 10.1371/journal.pone.0147428. eCollection 2016.


Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with <sup>99m</sup>Tc-Hynic-PEG-AE105.

Zhang X, Tian YE, Sun F, Feng H, Yang C, Gong X, Tan G.

Oncol Lett. 2015 Oct;10(4):2253-2258. Epub 2015 Jul 17.


Isothiocyanate-Functionalized Bifunctional Chelates and fac-[M(I)(CO)3](+) (M = Re, (99m)Tc) Complexes for Targeting uPAR in Prostate Cancer.

Kasten BB, Ma X, Cheng K, Bu L, Slocumb WS, Hayes TR, Trabue S, Cheng Z, Benny PD.

Bioconjug Chem. 2016 Jan 20;27(1):130-42. doi: 10.1021/acs.bioconjchem.5b00531. Epub 2015 Dec 30.


First-in-human uPAR PET: Imaging of Cancer Aggressiveness.

Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, Thurison T, Klausen TL, Holm S, Loft A, Berthelsen AK, Ploug M, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A.

Theranostics. 2015 Sep 13;5(12):1303-16. doi: 10.7150/thno.12956. eCollection 2015.


Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.

Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A.

J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.


uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.

Persson M, Juhl K, Rasmussen P, Brandt-Larsen M, Madsen J, Ploug M, Kjaer A.

Mol Pharm. 2014 Aug 4;11(8):2796-806. doi: 10.1021/mp500177c. Epub 2014 Jul 1.


Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.

Persson M, El Ali HH, Binderup T, Pfeifer A, Madsen J, Rasmussen P, Kjaer A.

Nucl Med Biol. 2014 Mar;41(3):290-5. doi: 10.1016/j.nucmedbio.2013.12.007. Epub 2013 Dec 18.


Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.

Persson M, Hosseini M, Madsen J, Jørgensen TJ, Jensen KJ, Kjaer A, Ploug M.

Theranostics. 2013 Aug 3;3(9):618-32. doi: 10.7150/thno.6810. eCollection 2013.


First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.

Persson M, Liu H, Madsen J, Cheng Z, Kjaer A.

Nucl Med Biol. 2013 Jul;40(5):618-24. doi: 10.1016/j.nucmedbio.2013.03.001. Epub 2013 Apr 18.


<sup>177</sup>Lu-Labeled DOTA-conjugated AE105 peptide (Asp-Cha-Phe-(d)Ser-(d)Arg-Tyr-Leu-Trp-Ser-CONH<sub>2</sub>).

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Sep 13 [updated 2012 Nov 8].


<sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-<i>N</i>,<i>N</i>',<i>N</i>'',<i>N</i>'''-tetraacetic acid-Asp-cyclohexylalanine-Phe-d-Ser-d-Arg-Tyr-Leu-Trp-Ser-NH<sub>2</sub> (AE105-NH<sub>2</sub>).

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 May 18 [updated 2012 Aug 23].

Supplemental Content

Loading ...
Support Center